AG1 ingredients full list: what the evidence shows

AG1 lists 75 ingredients across its label. The problem is that most of them sit inside named blends where individual doses are hidden. One published RCT exists on the product itself, La et al. (2024), and it found modest gut microbiome shifts in healthy adults but no clinically significant outcomes. That's the honest starting point for this conversation.

A 75-ingredient label with hidden doses isn't transparency. It's the appearance of transparency dressed up in a very expensive serving.

From this read

What the evidence actually shows

Let me be direct about what the published literature on AG1 actually contains. There is one product-level RCT. La et al. (2024) ran a randomised, double-blind, placebo-controlled trial in healthy adults and found that AG1 supplementation produced measurable changes in gut microbiome composition. Bifidobacterium and Lactobacillus counts shifted. That is worth noting. What the study did not show was any statistically significant improvement in clinical endpoints. No meaningful changes in energy, cognition, immune markers, or body composition were reported at the doses and duration studied.

That is not a condemnation of every ingredient in the formula. Several individual ingredients have credible standalone evidence. The problem is that product-level evidence and ingredient-level evidence are not the same thing. When you combine 75 ingredients at undisclosed doses, you cannot assume the clinical findings from single-ingredient trials transfer cleanly to the blend. Interactions exist. Doses get diluted. Bioavailability changes in complex matrices.

Functional food science has been making this point for years. Vanin et al. (2023) reviewed bioactive ingredients in functional foods and noted that the gap between a biologically active compound and a demonstrably effective product is often wider than marketing suggests. The dose, the form, and the delivery matrix all matter. A label listing an ingredient is not evidence that the ingredient is present at a dose that does anything meaningful.

Green tea extract, for instance, has a reasonable body of evidence behind specific polyphenol fractions at specific doses. Becker et al. (2020) catalogued the Camellia sinensis-derived ingredient family extensively, noting that bioactivity varies substantially by preparation method and concentration. AG1 lists "green tea extract" without specifying the standardisation percentage or the milligram dose. That is not a minor omission.

What named blends actually hide, and why it matters

AG1's label groups ingredients into several named complexes: an "Alkaline, Nutrient-Dense Raw Food Complex", a "Nutrient Dense Extracts, Herbs and Antioxidants" blend, a probiotic layer, and others. Each complex lists a total weight. Individual ingredient amounts within each complex are not disclosed.

This is legal. Under current UK food supplement regulations and the equivalent EU framework, a manufacturer can list a blend total without breaking out individual components. The law requires that all ingredients appear on the label by name. It does not require that you know how much of each one you're getting.

The practical consequence is this: you cannot verify whether any individual ingredient in a named blend is present at a dose that matches the clinical literature. An ingredient might be present at a clinically relevant amount. It might be present at a fraction of that amount, included primarily to justify its appearance on the label. From the outside, you cannot tell.

I find this genuinely frustrating. Not because AG1 is uniquely bad, they are doing what most of the industry does, but because the practice makes honest comparison almost impossible. When I look at a supplement label, I want to know whether the dose I'm taking matches the dose in the studies being cited. With a named blend at an undisclosed breakdown, that question cannot be answered.

Ingredient transparency also matters for safety reasons. Some botanicals in AG1's formula, including ashwagandha and milk thistle, have known interactions with medications and documented adverse effects at higher doses. Without knowing the dose, a consumer cannot assess their individual risk. I've written separately about how environmental contamination compounds this problem in algae-sourced ingredients. If you're curious about that angle, the piece on wales polluted rivers what it means for outdoor life gives useful background on why sourcing and cultivation environment matter more than most supplement brands acknowledge.

The ingredients with actual clinical evidence, and what the doses need to be

Not everything in AG1's formula is poorly supported. Some ingredients have a credible evidence base. The issue is dose disclosure. Here is my read of the key ones.

Vitamins and minerals

AG1 discloses its vitamin and mineral amounts, because these are regulated as individual nutrients and must be listed per serving. The vitamin C content is disclosed, for example. [GB-NHC] Vitamin C contributes to the normal function of the immune system, contributes to normal energy-yielding metabolism, contributes to the reduction of tiredness and fatigue, contributes to normal collagen formation for the normal function of skin, and contributes to the protection of cells from oxidative stress. These are authorised claims, and the doses required to make them are well established. If AG1 lists vitamin C at a dose above the authorised threshold, the claim is legitimate. That part of the label I have no quarrel with.

Zinc is present in the formula. The evidence base for zinc's role in immune function is strong, and deficiency is more common than most people assume. If you want a deeper read on that, I'd point you to zinc deficiency what the evidence shows, which covers the clinical picture in detail.

Bayne et al. (2025) noted that vitamins in pharmaceutical and supplement products serve genuinely important physiological roles, but that the excipient context, meaning what surrounds them in a formulation, can affect absorption. A point worth keeping in mind when you're looking at a 75-ingredient powder.

Botanical extracts in the named blends

This is where the evidence gets thinner and the dose question becomes critical. AG1 includes ashwagandha, rhodiola, coenzyme Q10, astragalus, and a range of other botanical extracts. Each has a body of research behind it. None of that research tells you what happens when they are combined at undisclosed doses with 70 other ingredients.

Coenzyme Q10 (ubiquinol form) has some interesting mechanistic data. Research is ongoing and large-scale human trials at clinically relevant doses are limited, particularly in healthy populations rather than clinical ones. The same is true of astragalus, rhodiola, and most of the adaptogenic botanicals in the blend. The human data is thin, and I would be overstating it to claim otherwise.

Spirulina and chlorella

AG1 contains both. These are algae-derived ingredients, and the sourcing question matters more here than almost anywhere else in the formula. Algae grown in contaminated water can accumulate heavy metals, microcystins, and other compounds you do not want in a daily supplement. The piece on blue green algae is shutting down northern irelands lakes again covers the contamination risk in detail. AG1 states that its ingredients are tested for contaminants, but the testing protocols are not publicly disclosed in detail.

Camellia sinensis (green tea) extract

Green tea extract is a common inclusion in greens powders. Becker et al. (2020) conducted a thorough safety assessment of Camellia sinensis-derived ingredients and found that bioactivity varies substantially depending on the preparation method, the standardisation of EGCG content, and the dose. AG1 does not disclose the standardisation percentage or the milligram amount of its green tea extract. Without that, the inclusion tells you very little.

What a transparent label actually looks like

I built KōJō partly because I was tired of looking at labels that told me almost nothing useful. Radical transparency, to me, means every ingredient listed with its exact dose, its form, and the reason it is included. No hidden blends. No obscuring behind a "complex" name.

The KōJō Daily Formula lists every ingredient with its exact milligram amount and its physical form. Creatine monohydrate at 5, 000 mg, micronised. Glycine at 2, 000 mg, crystalline. Taurine at 2, 000 mg, crystalline. Vitamin C at 500 mg, crystalline. Aged garlic extract at 600 mg, dry extract powder, which research suggests may support cardiovascular health markers. Olive leaf extract at 500 mg, which some studies indicate may help maintain healthy blood pressure within the normal range. Grape seed extract at 200 mg, which preliminary research suggests may help support vascular function. Pine bark extract at 150 mg, which early evidence suggests may help with circulation and antioxidant activity. Every number is on the label because every number should be on the label.

[GB-NHC] Creatine increases physical performance in successive bursts of short-term, high intensity exercise. That is an authorised claim, and the dose in the formula, 5, 000 mg daily, matches the clinical evidence that underpins it.

For the botanical extracts in the formula, glycine, taurine, aged garlic extract, olive leaf extract, grape seed extract, and pine bark extract, I want to be straightforward: research is ongoing and large-scale human trials are limited. I include them because the mechanistic and early-stage evidence is interesting and the safety profile at these doses is well characterised.

That is what a transparent label looks like. Not 75 ingredients in unnamed blends. Specific numbers, specific forms, honest framing of what the evidence supports.

The regulatory gap that allows this to continue

I want to be fair here. AG1 is not breaking any rules. The supplement industry operates in a regulatory environment that permits named blends at undisclosed individual doses, allows broad health claims at product level, and does not require manufacturers to demonstrate that their specific formulation works at its specific doses before selling it.

This is a structural problem, not a company-specific one. Vanin et al. (2023) made the point clearly in the context of functional foods: the gap between ingredient-level evidence and product-level efficacy is rarely closed by manufacturers, and regulators rarely require it to be. The result is a market where a product can cite dozens of ingredient-level studies without any of them being directly applicable to the product as formulated.

The UK's Food Standards Agency and the MHRA have enforcement powers, but they are reactive rather than proactive. A product can sell for years before a complaint triggers scrutiny. The burden of proof sits with the regulator, not the manufacturer.

What this means for consumers is that label literacy matters more than it should. You need to know what a named blend means. You need to know that "clinically studied ingredients" is not the same as "clinically studied product". And you need to know that a long ingredient list is not, by itself, evidence of anything.

Allergen and safety considerations in complex blends

A 75-ingredient formula raises legitimate allergen questions. AG1 lists potential allergens on its label, but the complexity of the formula makes cross-reactivity harder to assess than in a simpler product.

Several ingredients in AG1's botanical blend, including various herbal extracts, belong to plant families with known sensitisation potential. Ramani et al. (2023) documented allergen complexity in multi-ingredient topical products, noting that the more ingredients a formulation contains, the harder it becomes to identify the causative agent when a reaction occurs. The same logic applies to ingestible supplements. Needle et al. (2026) reinforced this point in the context of complex ingredient matrices, where sensitisation risk is harder to predict than with single-ingredient products.

This is not a reason to avoid complex supplements categorically. It is a reason to know what you are taking and at what dose. That question keeps returning to the same structural issue: when individual doses within a blend are not disclosed, you cannot fully assess your own risk.

Methylxanthines, including caffeine from guarana or green tea, appear in various greens powders. Cherian et al. (2024) conducted a safety assessment of methylxanthines and found that dose-dependent effects are significant, and that cumulative intake from multiple sources warrants attention. If you drink coffee and take a greens powder containing guarana, you may be consuming more total caffeine than you realise, particularly if the greens powder dose is not disclosed.

Frequently asked questions

My honest take

I've spent a lot of time with the AG1 label. I understand the appeal. It is a genuinely well-marketed product, and the people behind it are not stupid. They have built something that feels thorough, that looks scientific, and that has a loyal following.

But when I read the label carefully, I keep coming back to the same problem. I cannot tell whether the ingredients I care about are present at doses that match the clinical literature. I cannot verify that because the doses are not disclosed. That is the fundamental issue, and no amount of impressive ingredient naming resolves it.

The one published RCT, La et al. (2024), is a start. It is better than nothing. But it is one study in healthy adults with no significant clinical outcomes at the primary endpoints. That is a thin evidence base for a product that costs what AG1 costs.

I also think the complexity argument cuts against AG1, not for it. More ingredients is not better. Seventy-five ingredients at sub-threshold doses may do less than eight ingredients at clinically meaningful doses. The evidence for that position is not definitive, but it is the more scientifically conservative read. Vanin et al. (2023) and Bayne et al. (2025) both point toward dose and form as the primary drivers of efficacy. A long list of ingredients is not a substitute for that.

What I built with KōJō is deliberately simpler. Fewer ingredients, every one disclosed, every dose matching the published evidence where that evidence exists. I am not claiming my approach is the only valid one. I am claiming it is more honest. And for me, in a category where trust is the product as much as anything else, that matters more than anything else on the label.

If you are evaluating any supplement, including mine, the questions are the same. What is the dose? What is the form? Is there product-level evidence or only ingredient-level evidence? And are the claims on the label authorised, or are they extrapolations from loosely related studies? Those questions will serve you better than any ingredient list, however long.

This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement regimen.